This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Randall ME , Filiaci V , McMeekin DS , von Gruenigen V , Huang H , Yashar CM , Mannel RS , Kim JW , Salani R , DiSilvestro PA , Burke JJ , Rutherford T , Spirtos NM , Terada K , Anderson PR , Brewster WR , Small W , Aghajanian CA , Miller DS
Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer
J Clin Oncol. 2019 Jul 20;37(21) :1810-1818
PMID: 30995174 PMCID: PMC6804858 URL: https://www.ncbi.nlm.nih.gov/pubmed/30995174
AbstractPURPOSE: The primary objective was to determine if vaginal cuff brachytherapy and chemotherapy (VCB/C) increases recurrence-free survival (RFS) compared with pelvic radiation therapy (RT) in high-intermediate and high-risk early-stage endometrial carcinoma. PATIENTS AND METHODS: A randomized phase III trial was performed in eligible patients with endometrial cancer. Eligible patients had International Federation of Gynecology and Obstetrics (2009) stage I endometrioid histology with Gynecologic Oncology Group protocol 33-based high-intermediate-risk criteria, stage II disease, or stage I to II serous or clear cell tumors. Treatment was randomly assigned between RT (45 to 50.4 Gy over 5 weeks) or VCB followed by intravenous paclitaxel 175 mg/m(2) (3 hours) plus carboplatin (area under the curve, 6) every 21 days for three cycles. RESULTS: The median age of the 601 patients was 63 years, and 74% had stage I disease. Histologies included endometrioid (71%), serous (15%), and clear cell (5%). With a median follow-up of 53 months, the 60-month RFS was 0.76 (95% CI, 0.70 to 0.81) for RT and 0.76 (95% CI, 0.70 to 0.81) for VCB/C (hazard ratio, 0.92; 90% confidence limit, 0.69 to 1.23). The 60-month overall survival was 0.87 (95% CI, 0.83 to 0.91) for RT and 0.85 (95% CI, 0.81 to 0.90) for VCB/C (hazard ratio, 1.04; 90% confidence limit, 0.71 to 1.52). Vaginal and distant recurrence rates were similar between arms. Pelvic or para-aortic nodal recurrences were more common with VCB/C (9% v 4%). There was no heterogeneity of treatment effect with respect to RFS or overall survival among clinical or pathologic variables evaluated. CONCLUSION: Superiority of VCB/C compared with pelvic RT was not demonstrated. Acute toxicity was greater with VCB/C; late toxicity was similar. Pelvic RT alone remains an effective, well-tolerated, and appropriate adjuvant treatment in high-risk early-stage endometrial carcinomas of all histologies.
Notes1527-7755 Randall, Marcus E Filiaci, Virginia McMeekin, D Scott von Gruenigen, Vivian Huang, Helen Yashar, Catheryn M Mannel, Robert S Kim, Jae-Weon Salani, Ritu DiSilvestro, Paul A Burke, James J Rutherford, Thomas Spirtos, Nick M Terada, Keith Anderson, Penny R Brewster, Wendy R Small, William Aghajanian, Carol A Miller, David S U10 CA180868/CA/NCI NIH HHS/United States U10 CA027469/CA/NCI NIH HHS/United States P30 CA008748/CA/NCI NIH HHS/United States UG1 CA233302/CA/NCI NIH HHS/United States UG1 CA233191/CA/NCI NIH HHS/United States U10 CA180838/CA/NCI NIH HHS/United States U10 CA180822/CA/NCI NIH HHS/United States UG1 CA233290/CA/NCI NIH HHS/United States UG1 CA189867/CA/NCI NIH HHS/United States UG1 CA233331/CA/NCI NIH HHS/United States UG1 CA233193/CA/NCI NIH HHS/United States U10 CA037517/CA/NCI NIH HHS/United States Clinical Trial, Phase III Journal Article Research Support, N.I.H., Extramural United States J Clin Oncol. 2019 Jul 20;37(21):1810-1818. doi: 10.1200/JCO.18.01575. Epub 2019 Apr 17.